Petvivo Holdings Inc ( (PETV) ) has released its Q4 earnings. Here is a breakdown of the information Petvivo Holdings Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PetVivo Holdings Inc., a biomedical company specializing in medical therapeutics for equines and companion animals, reported its fiscal 2025 results, highlighting significant growth and strategic advancements.
PetVivo Holdings Inc. announced a 17% increase in revenues to a record $1.1 million for fiscal 2025, driven by its expansion into the companion animal market with its lead product, Spryng with OsteoCushion Technology. The company also reported a decrease in net loss by 27% to $8 million, supported by strategic restructuring and cost reduction efforts.
Key financial highlights include a 31% increase in national distributor network sales, contributing 85% of total revenues, and a 15% rise in gross profit. Operationally, PetVivo reached a milestone with Spryng being administered by over 1,000 veterinary clinics across the U.S. and entered a strategic alliance with Digital Landia, Inc. for AI solutions in animal care. The company also signed a licensing agreement with VetStem, Inc. for a new regenerative product, PrecisePRP.
Looking ahead, PetVivo Holdings Inc. is optimistic about its growth prospects, with plans to further expand its market reach and product offerings. The company anticipates continued strong sales momentum and market penetration in fiscal 2026, supported by its strategic partnerships and expanded distribution network.